- Home
- VGI vs MDXH Comparison
VGI vs MDXH Comparison
Compare VGI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | VGI | MDXH |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 167.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VGI | MDXH |
|---|---|---|
| Price | $7.75 | $3.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 46.0K | ★ 182.7K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 12.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $103,069,000.00 |
| Revenue This Year | N/A | $23.34 |
| Revenue Next Year | N/A | $22.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 21.68 |
| 52 Week Low | $6.68 | $1.35 |
| 52 Week High | $7.99 | $5.33 |
Technical Indicators
Market Signals| Indicator | VGI | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 38.93 |
| Support Level | $7.79 | $3.25 |
| Resistance Level | $7.86 | $3.74 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 20.00 | 25.45 |
Price Performance
Historical ComparisonAbout VGI Virtus Global Multi-Sector Income Fund of Beneficial Interest
Virtus Global Multi-Sector Inc is a United States based fund. Its investment objective is to maximize current income while preserving capital. The Fund seeks to achieve its investment objective by applying extensive credit research to capitalize on opportunities across undervalued areas of the international bond markets.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.